1-((2-Bromoquinoxalin-6-YL)methyl)-4-(4-isopropylphenyl)-6-(prop-2-YN-1-yloxy)quinazolin-2(1H)-one
Axt914 is under investigation in clinical trial NCT00417261 (Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.).